Colorectal cancer is the second leading cause of cancer-related death in the U.S. for men and women combined, according to the American Cancer Society, and a lack of screening can exacerbate the problem.
Category: Gastroenterology and Endoscopy
Endoscopy system with patient VR goggles cleared for sale
Medical device company EvoEndo has been cleared by the FDA to market and sell its EvoEndo single-use endoscopy system.
Gastroenterology consolidation shows no signs of slowing
The gastroenterology sector continued to experience rapid consolidation in the fourth quarter, according to a market update from Provident.
Does Gastro Health have new competition? 3 insights for 2022
Gastroenterology management companies Gastro Health, GI Alliance and United Digestive made big moves in 2021, accelerating the consolidation of the industry.
AI will change healthcare ‘in ways we have not imagined,’ gastroenterologist says
Vivek Kaul, MD, a gastroenterologist at University of Rochester (N.Y.) Medical Center and Strong Memorial Hospital, joined Becker’s ASC Review to discuss the forces deciding the future of healthcare and how ASCs can thrive in a competitive market.
The next GI trend: More advanced-stage cancer
As the COVID-19 pandemic demanded all hands on deck in the medical community, and patients put off preventive care, many other medical services fell by the wayside. The resulting ripple effects may be felt for years to come.
New model predicts treatment response of chemotherapy, immunotherapy for gastric cancer
A new model could help determine a patient’s most effective treatment option for gastric cancer.
Motus GI wins FDA nod for colonoscopy device
The FDA granted Motus GI market clearance for its second-generation Pure-Vu EVS system.
4 ways GI ASCs can thrive in a competitive market
The lowering of the colorectal cancer screening age and the acceleration of the outpatient migration leaves gastroenterology ASCs and endoscopy centers primed for growth.
Oral microbiome therapy shows promise fighting diarrhea-causing bacteria, study says
Oral microbiome therapy SER-109 could be helpful in fighting recurrent Clostridioides difficile, which causes diarrhea and colitis, according to a study published Jan. 20 in The New England Journal of Medicine.
